Evidence map›Paper›PMID 39367110›Full record

ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2025

State-of-the-art application of nanoparticles in radiotherapy: a platform for synergistic effects in cancer treatment.

Mehrnaz Mostafavi, Farhood Ghazi, Mahboobeh Mehrabifard, Vahid Alivirdiloo, Mobasher Hajiabbasi, Fatemeh Rahimi, Ahmad Mobed, Gholamreza Taheripak, Marzieh Ramezani Farani, Yun Suk Huh and 2 more

Abstract readReview
In one paragraph

Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Nanoparticle radiosensitizers in cancer radiotherapy: bridging preclinical promise and clinical reality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  4. Article
  5. Advancing brain immunotherapy through functional nanomaterials.Drug delivery and translational research · 2026
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mehrnaz MostafaviFaculty of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farhood GhaziFaculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
Mahboobeh MehrabifardHormozgan University of Medical Sciences, Bandarabas, Iran.
Vahid AlivirdilooRamsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran.
Mobasher HajiabbasiIslamic Azad University of Tonekabon, Tonekabon, Iran.
Fatemeh RahimiDivision of Clinical Laboratory, Zahra Mardani Azar Children Training Research and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Ahmad MobedSocial Determinants of Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Gholamreza TaheripakDepartment of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Marzieh Ramezani FaraniNanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, Incheon, Korea (Republic of).
Yun Suk HuhNanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, Incheon, Korea (Republic of).
Salar BakhtiyariDepartment of Clinical Biochemistry, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Iraj AlipourfardIraj Alipourfard, Institute of Physical Chemistry, Polish Academy of Sciences, Marcina Kasprzaka 44/52, 01-224, Warsaw, Poland. ialipourfard@ichf.edu.pl.ORCID 0000-0001-5164-8606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy (RT) is a gold standard cancer treatment worldwide. However, RT has limitations and many side effects. Nanoparticles (NPs) have exclusive properties that allow them to be used in cancer therapy. Consequently, the combination of NP and RT opens up a new frontier in cancer treatment. Among NPs, gold nanoparticles (GNPs) are the most extensively studied and are considered ideal radiosensitizers for radiotherapy due to their unique physicochemical properties and high X‑ray absorption. This review analyzes the various roles of NPs as radiosensitizers in radiotherapy of glioblastoma (GBS), prostate cancer, and breast cancer and summarizes recent advances. Furthermore, the underlying mechanisms of NP radiosensitization, including physical, chemical, and biological mechanisms, are discussed, which may provide new directions for next-generation GNP optimization and clinical transformation.

Indexed as

NanoparticlesNeoplasmsRadiation-Sensitizing AgentsRadiotherapyAnimalsBreast NeoplasmsGlioblastomaGoldHumansProstatic NeoplasmsGoldRadiation-Sensitizing AgentsBreast cancerGlioblastoma (GBS)Nanoparticles (NPs)Prostate cancer (PCa)Radiotherapy (RT)

Identifiers

PMID39367110
PMCPMC12119707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.